Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/
Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd. Daniel is recognized for pairing strategic focus with disciplined execution, and for building leadership teams and operating cultures capable of sustained high performance. He joins Alpega Group at a pivotal moment, with the mandate and experience to drive its next phase of profitable growth.
“Alpega brings together strong software assets and a meaningful presence across the transportation ecosystem,” said Daniel Cohen. “As the industry becomes more complex and fragmented, the opportunity is to simplify how transportation is managed and executed through solutions that increase trust and efficiency across the value chain. I’m looking forward to working closely with the team and the Board to build on our strong foundation and continue delivering market-leading products, supported by operational excellence and a culture that drives sustained performance.”
Under DeLaughter’s leadership, Alpega Group has strengthened its position as an industry innovator, expanded its product capabilities, and deepened relationships with shippers, carriers, and logistics partners around the world. His guidance has been instrumental in enhancing Alpega’s suite of software solutions and driving sustainable growth across key markets.
Alpega’s platform has evolved from a number of acquisitions including iNet, Transwide, Teleroute, TenderEasy and Wtransnet. This powerful set of tools includes a comprehensive TMS, transport execution capability, freight procurement and freight exchanges which make up Alpega’s digital transportation platform.
The Board expressed deep appreciation for DeLaughter’s leadership and continuity during the transition.
“On behalf of the entire Board, we thank Todd for his exceptional contributions as CEO,” said Chairman Nikolay Pargov. “We are delighted that he will continue to support the company as a trusted advisor. We have a strong conviction that under Daniel’s guidance, Alpega will enter a new phase of accelerated growth and innovation. The group has strong foundations, refreshed strategy, and a renewed, very talented leadership team. We continue pursuing our goal to deliver industry-leading performance.”
“It has been a privilege to lead Alpega Group through such an important chapter,” said Todd DeLaughter. “I am incredibly proud of what our teams have accomplished and confident that the company is well-positioned for growth above market expectations, Daniel is a strong, visionary leader, and I look forward to supporting him and the company in my advisory role.”
About Alpega Group
Alpega Group is a leading pan-European logistics software company offering end-to-end solutions that empower shippers, carriers, and logistics professionals to streamline and optimize supply chain operations. With decades of industry expertise, Alpega provides powerful Transportation Management Systems (TMS), a well-connected and collaborative Transport Execution Platform, Freight Exchange solutions, and digital tools that drive efficiency, visibility, and collaboration across the transportation ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108528648/en/
Contact
Media Contact:
Ceren Fuchs
Director of Communications
ceren.fuchs@alpegagroup.com
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii
“This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.”
Cardiovascular disease is the leading cause of death in Europeiii and for women worldwide,iv however it remains understudied, under-recognized, under-diagnosed and under-treated.v
Nilemdo® is the first and only treatment in its class available in these markets and provides healthcare professionals with a new therapy to reduce cardiovascular risk in patients unable to achieve adequate LDL-C reduction with statins or other lipid-lowering therapies, or in patients who are statin-intolerant or for whom statins are contraindicated.
Under the terms of the agreement, Organon will distribute and promote Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway. Daiichi Sankyo Europe will remain the marketing authorization holder for the product and Organon will be local representative in the territory.
About Nilemdo®
Nilemdo® is a lipid-lowering drug containing bempedoic acid, which inhibits ATP-citrate lyase, a key enzyme in the cholesterol biosynthesis pathway. It was approved by the European Medicines Agency (EMA) in February 2020.
Indications and use in the EU:
Hypercholesterolaemia and mixed dyslipidaemia
Nilemdo® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or,
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Cardiovascular disease
Nilemdo® is indicated in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
- in patients on a maximum tolerated dose of a statin with or without ezetimibe or,
- alone or in combination with ezetimibe in patients who are statin-intolerant, or for whom a statin is contraindicated.
The recommended dose is one 180 mg tablet taken orally once daily. Nilemdo® can be taken with or without food. If a dose is missed, the patient should take the tablet immediately and resume the usual schedule the next day.
Nilemdo® is intended for oral use only. Complete dosage and administration instructions are provided in the medication leaflet which can be found here: Nilemdo, INN-bempedoic acid. Please consult with your healthcare professional.
Patients should be monitored regularly to assess the effectiveness and safety of the treatment, with adjustments made as needed based on individual response and tolerance.
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.
Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s expectations about regarding its commercialization agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway. Forward-looking statements may be identified by words such as “potential,” “mission,” “expects,” “will,” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K (as amended), Quarterly Reports on Form 10-Q (as amended), Current Reports on Form 8-K, and other SEC filings, available at the SEC’s Internet site (www.sec.gov). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
| _____________________________ |
i Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213-3223. doi:10.1093/eurheartj/ehac015 |
ii European Medicines Agency, Nilemdo (bempedoic acid) Summary of product characteristics, available here: Nilemdo, INN-bempedoic acid [last accessed: January 2026] |
iii WHO, Cardiovascular diseases, available here: Cardiovascular diseases EURO [last accessed: December 2025] |
iv European Society of Cardiology, Cardiovascular disease in women, available here: Cardiovascular Disease in Women [last accessed: December 2025] |
v Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385-2438. doi:10.1016/S0140-6736(21)00684-X |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107056646/en/
Contact
Media:
Karissa Peer
(614) 314-8094
Felicia Bisaro
(646) 703-1807
Investor:
Jennifer Halchak
(201) 275-2711
Abstract
Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/
Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint.
In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company continues to execute its growth and innovation strategy.
Strategic vision, deep industry expertise, and proven leadership
“We are delighted to welcome Arne to the Natus Sensory Board of Directors. His strategic vision, deep industry expertise, and proven leadership in driving global impact make him an ideal partner as we continue to scale our innovation and support customers worldwide. Arne’s insights will be invaluable as we build on our success and strive for continued excellence,” says Matthias Weber, Chairman of the Board of Directors, Natus Sensory.
“I am honoured to join the Board of Natus Sensory at such an exciting time in its growth journey. I look forward to working collaboratively with the Board and leadership team to support Natus Sensory’s mission and to contribute to its long-term strategic success,” says Arne Boye Nielsen.
About Natus Sensory
Natus Sensory is a global leader in solutions for assessing, fitting and screening in the areas of hearing, balance, vision and newborn care – making a meaningful difference in patient care. With a legacy of groundbreaking innovation, we are committed to improving outcomes for patients and supporting the daily work of healthcare professionals. At the core of our innovation is a dedication to listening to clinicians, ensuring every product addresses real-world challenges. Our solutions are known for their ease of use, reliability, and safety. Beyond products, Natus Sensory offers comprehensive training and education – empowering clinicians with the knowledge and support they need to deliver exceptional care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107392331/en/
Contact
For more information, please contact:
Catherine Conlon
Global Marketing & Communications
+45 22 36 40 52
Catherine.conlon@natus.com
TweetText
Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades.
Zilch to Acquire Fjord Bank to Kickstart European Expansion
Zilch, the consumer payments platform powering the future of commerce, today announces it has signed an agreement to acquire AB Fjord Bank, a Lithuania-based bank with approx. $120M in total assets that is authorised and regulated by the Bank of Lithuania and the European Central Bank.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107714872/en/
The acquisition will represent a major strategic milestone for Zilch, providing a European banking licence that will enable the accelerated rollout of its offering across Europe. Zilch will purchase 100% of Fjord Bank and will establish Lithuania as its European headquarters as a consequence of the transaction, using Vilnius as its operational and regulatory platform for expansion across Europe.
Launched in 2021, Fjord Bank is a profitable and fully regulated challenger bank, focusing on online consumer lending and savings products that have built a strong reputation for trust, transparency and digital delivery. This acquisition marks the next phase of Zilch’s growth, and will enable the business to passport its market-leading proposition across Europe with enhanced capital efficiency, whilst broadening its product capabilities.
The deal caps a transformational year for Zilch, during which the business announced that it had successfully raised over $175M in debt and equity funding, surpassed $200M annual revenue, secured a second Financial Conduct Authority (FCA) payments licence, launched its landmark Zilch Intelligent Commerce AI product and passed 5.5m registered customers.
The transaction is expected to complete in the second half of 2026, subject to regulatory approvals.
Philip Belamant, Co-Founder and CEO of Zilch, said: “This is a defining moment for Zilch as we build a platform that will power our international expansion. Not only does the deal give us a strong, trusted and fully regulated banking presence in Europe, but it represents a coming together of shared visions. Both businesses have been built on a founding principle of putting customers first and building financial products with the highest standards of protection and transparency. By combining Fjord’s banking capabilities and regulatory footprint with Zilch’s market-leading data, AI capabilities and unique operating model, we can scale a new generation of consumer finance across Europe, just as we have done in the UK.”
Veiko Kandla, CEO of Fjord Bank, said: “We are incredibly proud of what the Fjord team has built over the past five years. Having established the business and successfully scaled it, the time is now right to become part of a bigger mission. Joining Zilch provides the perfect opportunity, enabling us to accelerate growth, expand our product set and reach millions more customers without compromising on our consumer-first values.”
Olav Haugland, Chairman of the Supervisory Board of Fjord Bank, added: “As custodians of the bank, our priority was to find a home that could support the next phase of Fjord’s growth and ambition. We firmly believe we have found that with Zilch, and its outstanding leadership team and look forward to seeing the business continue to thrive as part of the group.”
About Zilch.
Zilch is the London-headquartered consumer payments platform making money go further. Launched in 2020 with a mission to eliminate high-cost credit, Zilch offers a new type of payments experience combining flexible ways to pay with meaningful rewards, putting consumers in control of their finances while bringing them closer to the brands they love. With over 5 million registered customers, Zilch uses its technology to connect its highly engaged user base with retailers and brands helping them acquire customers more efficiently whilst delivering consumers personalised rewards, benefits and discounts. Backed by leading global firms including AWS, Deutsche Bank and Visa, the business has rapidly scaled to become the UK and EMEA’s fastest-growing fintech unicorn, harnessing the power of credit, AI technology and data to improve financial outcomes for consumers and drive growth through rewiring the economics of global commerce.
Learn more at www.zilch.com
About Fjord Bank.
Fjord Bank is a fully digital challenger bank, headquartered in Vilnius, Lithuania. The company was established by a Nordic investor pool in 2017. After receiving a specialized banking license from the European Central Bank in 2019, the bank launched its services to the public in early 2021. Fjord Bank offers digital consumer finance and savings products, with a focus on the near-prime customer segment. The bank serves thousands of active customers, operating today in Lithuania, Estonia, the Netherlands, Germany, Spain, and Ireland.
Learn more at www.fjordbank.lt
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107714872/en/
Contact
Ryan Mendy, Chief Business Officer: comms@zilch.com
For any Press & Media enquiries, please contact: zilch@mhpgroup.com
TweetText
Zilch to Acquire Fjord Bank to Kickstart European Expansion; Acquisition will provide Zilch, the UK and EMEA’s fastest-growing fintech unicorn, with a European banking licence as it eyes international rollout
Chromavis Implements Transparency-One® to Help Strengthen Supply Chain Traceability and Sustainability Initiatives
Transparency-One, ISN®’s responsible sourcing platform built to help bring transparency to supply chain management, announced a new partnership with Chromavis, a premier full-service cosmetics manufacturer, to help improve supply chain traceability and responsible sourcing. Transparency-One will help Chromavis extend visibility beyond its direct suppliers, enhance data-driven decision-making, and accelerate progress toward its long-term sustainability and climate goals.
“With Chromavis newly implementing Transparency-One, we hope to gain greater visibility into every level of our supply chain,” said Pauline Costet, CSR Manager at Chromavis.
Headquartered in Offanengo, Italy, Chromavis develops and manufactures innovative cosmetic products exclusively for global beauty brands. Through its partnership with Transparency-One, Chromavis is enhancing traceability beyond its direct supplier tiers to gain a deeper understanding of its extended value chain.
Chromavis will leverage Transparency-One’s supply chain mapping tools, risk analysis dashboard, and document collection to support compliance with evolving global regulations and drive responsible sourcing practices across its operations. By 2030, the company aims to audit all suppliers for ethics and environmental performance, achieve full Roundtable on Sustainable Palm Oil (RSPO) compliance, and expand refill and reuse solutions across 30% of its product portfolio, objectives Transparency-One will help advance through stronger data visibility and supplier collaboration.
“Chromavis is setting a strong example for how manufacturers can integrate sustainability and transparency into every aspect of operations,” said Brittany Sizemore, Senior Vice President at Transparency-One. “Transparency-One is proud to help extend Chromavis’ visibility beyond direct suppliers, and take tangible steps toward its climate and ethical sourcing goals.”
For more information on ISN’s industry-leading software and services, visit isn.com.
About ISN
ISN is the global leader in contractor and supplier information management, with more than 20 years of experience connecting 850 Hiring Clients in capital-intensive industries with 85,000 active contractors and suppliers to promote safety, health, and sustainability in the workplace. ISN’s brands include ISNetworld®, a global online contractor and supplier management platform, Transparency-One®, a responsible sourcing platform built to bring transparency to supply chain management, and Empower®, a worker-level app built to keep workers moving forward.
ISN has 14 offices around the globe which provide award-winning support and training for its customers in more than 85 countries. ISN takes pride in leading worldwide efforts to improve the efficiency and effectiveness of contractor and supplier management systems and in serving as a world-class forum for sharing industry best practices, benchmarking performance, providing data insights among its members, and helping decision makers, including board members, ensure contractor and supplier risk is assessed and monitored. For more information, visit isn.com.
About Chromavis
Chromavis is a leading global innovator in color cosmetics, transforming creative ideas into sustainable beauty solutions. With a strong commitment to ethical practices and environmental stewardship, the company combines cutting-edge formulation expertise, industrial excellence, and artistic vision to help brands bring products to market responsibly and efficiently. Headquartered in Italy and part of the Fareva Group, Chromavis continues to advance the beauty industry through its focus on energy efficiency, refillable and reusable packaging, and sustainable product innovation. For more information, visit chromavis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107563169/en/
Contact
Media Contact
Alyssa Bruce
Walker Sands for ISN
isnpr@walkersands.com
PureSpectrum Announces Strategic Partnership with TA to Accelerate Next Phase of Growth
PureSpectrum, a leading market research technology company, today announced a strategic partnership with TA Associates (“TA”), a leading global private equity firm. The partnership marks an important milestone in PureSpectrum’s 10-year growth journey and will support the Company as it continues to accelerate innovation, scale its platform, and deepen value for customers across the market research ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107307241/en/
Launched in 2016, PureSpectrum operates a programmatic marketplace and sample management platform that connects market research firms, brands, and institutions with a broad, global network of survey respondents. The PureSpectrum Marketplace combines automation, dynamic allocation, and PureScore™, its AI-driven quality scoring system, delivering faster and more reliable access to high-quality human insights.
PureSpectrum’s Founder and Chief Executive Officer, Michael McCrary, along with the broader PureSpectrum leadership team, will remain meaningful shareholders and continue to lead the Company in close partnership with TA.
“PureSpectrum was built to raise the standard for quality, delivery, and simplicity in market research,” said McCrary. “TA’s deep experience supporting founder-led, high-growth businesses makes them an ideal partner as we continue to advance that mission. With TA’s support, we are well-positioned to invest behind our platform, expand our capabilities, and further simplify how researchers access and trust high-quality insights.”
Through the partnership, PureSpectrum will continue investing in its strategic roadmap, with a focus on product innovation and platform scalability. These investments will accelerate innovation, expand what’s possible across the market research ecosystem, address critical industry challenges, and deliver long-term value to its customers.
“Market research is undergoing a meaningful shift toward greater automation and AI-enabled workflows as demand for high-quality human data and sophisticated response validation continues to grow,” said Dylan Hallman, Senior Vice President at TA. “PureSpectrum sits at the intersection of these trends, and its marketplace model positions the Company to play a central role in how insights are generated and consumed in the years ahead.”
“PureSpectrum has built a differentiated, category-defining platform at a moment when data quality and automation have become mission-critical for business decisions,” said Jason Mironov, Managing Director at TA. “Michael and his team have demonstrated strong execution and a clear vision, and we are thrilled to partner with them to scale the platform, invest in innovation, and support customers as their needs continue to evolve.”
Goodwin Procter LLP served as legal counsel to TA, and Deloitte LLP served as financial advisor. Payne Enterprises also advised TA on the transaction. Piper Sandler & Co served as exclusive financial advisor to PureSpectrum, and Cooley LLP served as legal counsel to PureSpectrum.
About PureSpectrum
PureSpectrum, launched in 2016 and headquartered in California, is a leading market research technology company. PureSpectrum empowers insights professionals with a programmatic Marketplace and sample management platform that streamlines online surveys, facilitating millions of high-quality interviews annually. Researchers are empowered to make faster, more confident decisions with PureSpectrum’s comprehensive suite and proprietary PureScore™ respondent-level scoring system. Visit www.purespectrum.com for more information.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its core sectors, including technology, business services, financial services, and healthcare. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai, and Hong Kong. Learn more at www.ta.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107307241/en/
Contact
Media Contacts
For TA:
Maggie Benoit
mbenoit@ta.com
For PureSpectrum:
Stephanie Fuess
stephanie@purespectrum.com
Arm Announces Earnings Release Date for Third Quarter Fiscal Year Ended 2026
Arm Holdings plc (NASDAQ: ARM) will report financial results for the third quarter of fiscal year 2026 on Wednesday, Feb. 4, 2026, after market close. The company will host a conference call via audio webcast at 14:00 Pacific Time (17:00 Eastern Time / 22:00 Greenwich Mean Time) to review its financial results and business outlook.
The live audio webcast will be available at: https://edge.media-server.com/mmc/p/o443v7p2 and a replay of the conference call can be accessed on http://investors.arm.com/ shortly afterwards. The replay will be available for four weeks.
About Arm
Arm is the industry’s highest-performing and most power-efficient compute platform with unmatched scale that touches 100 percent of the connected global population. To meet the insatiable demand for compute, Arm is delivering advanced solutions that allow the world’s leading technology companies to unleash the unprecedented experiences and capabilities of AI. Together with the world’s largest computing ecosystem and 22 million software developers, we are building the future of AI on Arm.
All information is provided “as is” and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries or affiliates). All brands or product names are the property of their respective holders. © 1995-2026 Arm Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107140246/en/
Contact
Media
Kristen Ray
Kristen.Ray@arm.com
Investors
Arm Investor Relations
Investor.Relations@arm.com
WP Engine Acquires Big Bite
WP Engine, a global web enablement company providing premium products and solutions for websites built on WordPress Ⓡ[1], today announced its acquisition of Big Bite, a leading enterprise agency renowned for the development of advanced editorial tools that dramatically improve how global brands and media organizations create and share digital content.
A longstanding WP Engine agency partner, Big Bite has over a decade of experience developing newsroom platforms, publishing workflows, and specialized tools that combine editorial flexibility with technical excellence. Their publishing expertise has helped transform the digital ecosystems of some of the world’s biggest media brands, including The Times, The Wall Street Journal, New York Post, Metro, and Macworld. As part of this transaction, Big Bite’s agency business will be wound down, and its team will transition into WP Engine’s Engineering organization to help build products that enhance publishing solutions for customers and agency partners.
“Today’s acquisition advances WP Engine’s commitment to serve publishers with products that enable them to more efficiently create, organize, and share content,” said Ramadass Prabhakar, Chief Technology Officer at WP Engine. “Together, we’ve successfully aligned our capabilities to support some of the world’s biggest publishers, including ITP Media Group, and we are in a unique position to bring intelligent, purpose-built software solutions to market for agency partners and publishers that will improve how they deliver digital content and optimize workflows.”
“We are excited to bring our two organizations together to unlock growth and develop unique product offerings for digital agencies and brands that partner with WP Engine,” said Jason Agnew, Big Bite Chief Technology Officer and Co-Founder. “By uniting our strengths in engineering, we can provide even greater value to WP Engine’s agency partners looking to elevate publishing capabilities.”
Big Bite’s publishing expertise, focused on navigating the rapidly changing digital landscape with innovative solutions, will seamlessly integrate into the premium service WP Engine provides its network of global agency partners. To learn more about WP Engine, click here.
About WP Engine
WP Engine empowers companies and agencies of all sizes to build, power, manage, and optimize their WordPress websites and applications with confidence. The global technology company serves more than 1.5 million sites, providing premium, enterprise-grade solutions, tools, and services, including specialized hosting platforms for WordPress, industry-tailored agency solutions, and developer-centric tools like Local, Advanced Custom Fields, NitroPack, and more. WP Engine’s innovative technology and industry-leading expertise are why 8% of the web visits a WP Engine-powered site daily. Learn more at wpengine.com.
About Big Bite
Big Bite revolutionizes online publishing for global brands and newsrooms by developing scalable digital solutions and products, exclusively built on WordPress. With extensive experience in delivering large-scale projects, including several in partnership with WP Engine, the UK-based agency specializes in working with multi-faceted enterprise organizations that have numerous contributors, extensive content, and numerous challenges. Since its founding in 2011, Big Bite has designed and developed publishing ecosystems, high-traffic sites, custom themes, and innovative plugins on behalf of its impressive client portfolio, which includes brands such as The Times, The Wall Street Journal, the New York Post, Gumtree, Amnesty International, and Octopus Group.
[1] The WordPress® trademark is the intellectual property of the WordPress Foundation. WP Engine is not endorsed or owned by, or affiliated with, the WordPress Foundation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107821691/en/
Contact
Media Contact:
Lauren Cox
press@wpengine.com
OneSource Virtual Announces Strategic, Majority Growth Investment from TA
OneSource Virtual (OSV), a leading provider of HR and payments services for the Workday ecosystem, today announced a strategic, majority growth investment from TA Associates (TA), a leading global private equity firm. This investment will support the continuation of OSV’s organic growth, product innovation, and enhanced customer capabilities across the Workday ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107511710/en/
As part of the transaction, OSV founders, management, and employees will retain a significant minority stake in OSV. Halyard Capital and TCV will fully exit their stakes in OSV. Financial terms of the transaction will not be publicly disclosed.
Founded in 2008, OSV’s services and technology are purpose-built for the more than 1,400 Workday customers who trust OSV to handle payroll, tax, earned wage access, accounts payable, and benefits services. OSV provides a seamless, in-tenant experience for shared Workday clients, enabling them to execute time-sensitive business processes efficiently and accurately. OSV has grown its client base by 20% annually since 2020, highlighting the increasing value of its services for HR and Finance leaders.
“OSV’s proprietary technology, paired with our team’s deep Workday expertise and customer-first mindset, has enabled us to become a trusted partner for organizations managing complex, mission-critical processes within the Workday ecosystem,” said John Bax, CEO of OneSource Virtual. “We’re excited to partner with TA to build upon the strong foundation we’ve established. With access to TA’s experience and strategic resources, we intend to advance our technology platform, broaden the ways we support customers, and continue investing in the people and culture that define OSV.”
“OneSource Virtual has been a trusted Workday services and innovation partner for more than 17 years, providing scalable HCM and Financial Management services that allow Workday customers to focus on core business needs and not on administrative tasks,” said Matthew Brandt, Senior Vice President of Global Partners at Workday. “With OSV and TA working together, we welcome an expansion of OSV service and technology offerings purpose-built for Workday customers, further extending the value and possibilities of the Workday platform.”
“OSV has an excellent reputation as a leader in services for Workday’s U.S., Canada, and UKI clients. OSV has invested heavily in its technology and talent to manage administrative complexity for its clients,” said Roy Burns, Managing Director at TA. “We are excited to build on OSV’s well-earned success in partnership with John and the entire OSV team.”
“TA has spent considerable time evaluating the broader BPaaS landscape, and OSV stands out for its in-tenant delivery model, tech-enabled service approach, and deep alignment with the Workday ecosystem,” said Harry Taylor, Managing Director at TA. “Looking ahead, we see meaningful opportunity to continue to expand OSV’s product capabilities, including enhancements enabled by AI, and to introduce operational initiatives that further elevate the customer experience.”
Advisors
Weil, Gotshal & Manges LLP served as legal counsel to OSV. Goodwin Procter LLP served as legal counsel to TA.
About OneSource Virtual
OneSource Virtual delivers in-tenant technology and expert services to automate administrative and transactional tasks, including payroll, taxes, accounts payable, and benefits, within Workday. OSV has worked exclusively with Workday customers since 2008, with a services team that averages 10 years of Workday experience and 20 years of industry experience. With more than 1,400 customers, 95% retention, and over $200 billion in annual treasury movement, OSV helps organizations take their teams from transactional to transformational. To learn more, visit www.onesourcevirtual.com.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its core sectors, including technology, business services, financial services, and healthcare. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai, and Hong Kong. Learn more at www.ta.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107511710/en/
Contact
Media Contacts
For OneSource Virtual:
Brontë Schmidt
pr@onesourcevirtual.com
For TA:
Maggie Benoit
mbenoit@ta.com
Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom
Bial, an innovation-driven biopharmaceutical company, today announced the launch of KYNMOBI® (apomorphine hydrochloride) in the United Kingdom, the first sublingual film indicated for the intermittent treatment of OFF episodes in adult patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication1.
In the United Kingdom, it is estimated that around 166,000 people suffer from Parkinson’s disease,2 most of which may experience OFF periods at some point. These episodes occur when the medication, usually levodopa, becomes insufficient throughout the day, leading to the reappearance of motor symptoms such as stiffness, tremors, and difficulty moving, impacting daily activities and affecting their autonomy as well as their well-being3. In this context, rescue treatments, as a complement to regular antiparkinsonian medication, are essential. These types of on-demand therapies act quickly and specifically to relieve these symptoms and improve the quality of life for patients4.
Tom Foltynie, Consultant Neurologist and Professor of Neurology at the National Hospital for Neurology & Neurosurgery, Queen Square, London, said: “Motor fluctuations are a major concern for patients as Parkinson’s progresses. Oral doses of Levodopa can take an hour before they start to take effect, and some doses fail completely because of slow stomach emptying or competition for absorption from dietary protein. Identifying other mechanisms of administration for dopaminergic therapies is therefore of major importance and we look forward to assessing the benefits of sublingual apomorphine in our PD patients experiencing this problem.”
Camille Carroll, Consultant Neurologist and Professor of Clinical Neuroscience at the Translational and Clinical Research Institute at Newcastle and Faculty of Health, University of Plymouth said: “I am delighted to see Kynmobi becoming available as another therapeutic option in the UK for Parkinson’s disease. It is by having a breadth of therapies to select from that we, as clinicians, are able to provide care personalised to the requirements and preferences of patients. It is particularly pleasing to see a new formulation coming through to market based on trials that UK sites helped to deliver. By actively engaging with research opportunities and supporting trial delivery we can all ensure that people with Parkinson’s continue to benefit from innovative therapies.”
The availability of a sublingual formulation of apomorphine represents a significant advancement in the delivery of a well-established treatment for Parkinson’s disease. Thanks to this route of administration, the well-known first-pass effect is avoided, thus achieving a rapid onset of action and supporting patients experiencing intermittent OFF episodes. The sublingual film is placed under the tongue and kept in that position until it completely dissolves.
The efficacy and safety of sublingual apomorphine in the intermittent treatment of “OFF” episodes in adult patients with Parkinson’s disease (PD) has been demonstrated in two Phase III studies, one double-blind, placebo-controlled (Study 1) and one open-label, randomised, crossover, active-comparator (subcutaneous apomorphine) trial utilising a single-blinded rater (study 2). These studies were similar in design in that each had a titration phase in which subjects were titrated to an effective and tolerable dose.1
In Study 1, treatment with sublingual apomorphine resulted in a statistically significant mean improvement in MDS-UPDRS Part III score at Week 12 compared with placebo (primary endpoint; LS mean difference –7.6; P=0.0002; N=109), and a higher proportion of patients achieving a subject-rated full ON response within 30 minutes of dosing (key secondary endpoint, P=0.0426) compared with placebo.1
In Study 2, sublingual apomorphine demonstrated therapeutic efficacy comparable to subcutaneous apomorphine (N=74). After four weeks of treatment in each crossover period, the LS mean change in MDS-UPDRS Part III scores from pre-dose to 90 minutes post-dose (primary endpoint) was –13.55 (95% CI: –16.39, –10.70) for sublingual apomorphine and –13.78 (95% CI: –16.65, –10.90) for subcutaneous apomorphine, indicating numerically similar improvements with both formulations.1
The most common adverse reactions reported in pooled analyses for two phase II and two phase III clinical studies were nausea (20.5%) during titration phase, and nausea (22.0%), somnolence (8.5%) and dizziness (5.9%) during maintenance phase. Oropharyngeal adverse events (swelling, oedema, pain, irritation, ulceration) were also commonly observed in the patients treated with sublingual apomorphine.1
“At Bial, our commitment to people living with Parkinson’s is unwavering. OFF episodes can affect daily life significantly, turning everyday moments into real challenges. We are delighted to offer a treatment option that helps patients and healthcare professionals manage symptoms as difficult and disabling as OFF episodes can be. Bringing this medicine to UK patients – the fifth country to do so – highlights Bial’s ongoing dedication to Parkinson’s patients and marks an important step in the company’s ambition, aiming to be a reference and a top partner in neurology and Parkinson’s Disease in Europe,” says Magarete Ruiz, Country Manager of Bial in United Kingdom.
The commercialisation of KYNMOBI® (apomorphine hydrochloride) sublingual film in the United Kingdom follows a decentralised approval process in Europe. Following an agreement with Sumitomo Pharma America, Inc. (SMPA), Bial received exclusive commercial license rights to commercialise apomorphine hydrochloride sublingual film in the European Union, the European Economic Area, and the United Kingdom.
About Parkinson’s Disease and OFF Episodes
Parkinson’s disease affects everyone differently, and most experience ON and OFF episodes. ONs are the periods during which the patient responds to medication and experiences satisfactory improvement in motor and non-motor symptoms. OFF episodes occur when the patient experiences changes in their clinical state, i.e. motor and/or non-motor symptoms may reappear or worsen5,6. OFF episodes can manifest as Parkinsonism with tremor, rigidity, bradykinesia, gait impairment, and falling, in addition to non-motor symptoms7. Within 2-5 years, up to 50% of patients may experience some degree of motor complications, and between 80% to 100% of Parkinson’s disease patients will develop motor complications after 10 years of dopaminergic therapy8.
About Bial
BIAL is an innovation-driven pharmaceutical company dedicated to improving the health and lives of people worldwide. With a strong commitment to therapeutic innovation, BIAL has established an ambitious R&D programme, consistently investing over 20% of its annual revenue in this area. The company focuses on two key areas with high unmet medical needs: neurosciences and rare diseases. In Europe, BIAL operates manufacturing facilities and an R&D centre at its headquarters in Portugal, and maintains subsidiaries in Spain, Germany, the United Kingdom, Italy, and Switzerland. In addition, BIAL is present in the United States and selected emerging markets. As part of its international growth strategy, the company collaborates with established partners through strategic alliances and licensing agreements to expand access to its healthcare solutions. Today, BIAL’s products are available in more than 50 countries, advancing its mission to deliver transformative medicines that empower patients’ lives.
About Bial Pharma UK Ltd
Founded in 2010, Bial Pharma Ltd is the British subsidiary of Bial, committed to providing patients and the scientific community with innovative therapeutic options. Based in Windsor, Berkshire, Bial Pharma UK Ltd markets medicinal specialities for Parkinson’s disease and Epilepsy. The company actively supports clinical trials and independent research studies in the United Kingdom, contributing to the advancement of scientific knowledge and patient care.
References
- Kynmobi (apomorphine hydrochoride) – Summary of Product Characteristics – available on www.medicines.org.uk (last accessed: December 2025)
- Parkinson’s UK – Parkinson’s statistics; available on www.parkinsons.org.uk/about-us/parkinsons-statistics (last accessed: December 2025)
- Olanow, C. W., Poewe, W., Rascol, O., & Stocchi, F. (2021). On‐Demand Therapy for OFF Episodes in Parkinson’s Disease. Movement Disorders, 36(10), 2244-2253. https://doi.org/10.1002/mds.28726
- Hauser, R. A., LeWitt, P. A., & Comella, C. L. (2021). On demand therapy for Parkinson’s disease patients: Opportunities and choices. Postgraduate Medicine, 133(7), 721-727. https://doi.org/10.1080/00325481.2021.1936087
- Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1-136.
- Chou KL, Stacy M, Simuni T, et al. The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9-16.
- Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D; CTH-300 Study investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020 Feb;19(2):135-144. doi: 10.1016/S1474-4422(19)30396-5. Epub 2019 Dec 7. PMID: 31818699
- Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson’s Disease. Semin Neurol. 2017 Apr;37(2):147-157. doi: 10.1055/s-0037-1602423. Epub 2017 May 16. PMID: 28511255; PMCID: PMC5990008.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107970009/en/
Contact
Media:
Bial
Susana Vasconcelos
Director, Communication
T. +351229866100 | E. susana.vasconcelos@bial.com
Abstract
Bial launches KYNMOBI® in the UK, the first sublingual film indicated for the intermittent treatment of OFF episodes in adult patients with PD.
TweetText
Bringing this medicine to UK patients highlights Bial’s ongoing dedication to Parkinson’s patients and marks an important step in the company’s ambition, aiming to be a reference and a top partner in neurology and Parkinson’s Disease in Europe.
